Skip to main content

Advertisement

SpringerLink
Log in

The effect of interferon β-1a on optic neuritis relapse in patients with multiple sclerosis

  • Neuro-ophthalmology
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

To evaluate the clinical effect of interferon β-1a on optic neuritis (ON) relapse in patients with multiple sclerosis (MS) in Taiwan.

Methods

Data were collected from 23 MS patients with ON at National Taiwan University Hospital between January 1, 1993 and February 1, 2007. Twenty-three MS patients with ON received interferon β-1a (Rebif) 44 µg via subcutaneous injection three times weekly. All patients received corticosteroids pulse therapy followed by oral prednisolone for acute ON. The annual relapse rate (ARR) of ON in these MS patients before and after the use of interferon β-1a (Rebif) was the main clinical parameter of outcome in this study.

Results

The ARR of ON was lower in the posttreatment period than in the pretreatment period (P = 0.0068). Thirteen patients (56.5%) had improved final visual acuity (>2 lines), and the other ten patients (43.5%) had stable final visual outcome (−2 lines < X < 2 lines). In addition, no recurrence of ON was noted in 15 patients (65.2%) during the posttreatment period.

Conclusions

The use of interferon β-1a 44 µg via subcutaneous injection three times weekly did not increase the ON attacks in MS patients receiving this treatment. In addition, beneficial effects were found with the use of interferon β-1a on these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Söderström M, Jin YP, Hillert J, Link H (1998) Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 50:708–714

    PubMed  Google Scholar 

  2. Ikuta F, Zimmerman HM (1976) Distribution of plaques in seventy autopsy cases of multiple sclerosis in the United States. Neurology 26:26–28

    CAS  PubMed  Google Scholar 

  3. Toussaint D, Perier O, Verstappen A, Bervoets S (1983) Clinicopathological study of the visual pathways, eyes, and cerebral hemispheres in 32 cases of disseminated sclerosis. J Clin Neuroophthalmol 3:211–220

    CAS  PubMed  Google Scholar 

  4. Sandberg-Wollheim M, Bynke H, Cronqvist S, Holtås S, Platz P, Ryder LP (1990) A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol 27:386–393

    Article  CAS  PubMed  Google Scholar 

  5. Rodriquez M, Siva A, Cross SA, O'Brien PC, Kurland LT (1995) Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 45:244–250

    Google Scholar 

  6. O’Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, Rudge P, McDonald WI, Miller DH (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121:495–503

    Article  PubMed  Google Scholar 

  7. Kira JI (2003) Multiple sclerosis in the Japanese population. Lancet Neurol 2:117–127

    Article  PubMed  Google Scholar 

  8. Hung TP, Landsborough D, Hsi MS (1976) Multiple sclerosis amongst Chinese in Taiwan. J Neurol Sci 27:459–484

    Article  CAS  PubMed  Google Scholar 

  9. Tsai CP, Yuan CL, Yu HY, Chen C, Guo YC, Shan DE (2004) Multiple sclerosis in Taiwan. J Chin Med Assoc 67:500–505

    PubMed  Google Scholar 

  10. Lin YC, Yen MY, Hsu WM, Lee HC, Wang AG (2006) Low conversion rate to multiple sclerosis in idiopathic optic neuritis patients in Taiwan. Jpn J Ophthalmol 50:170–175

    Article  PubMed  Google Scholar 

  11. Woung LC, Lin CH, Tsai CY, Tsai MT, Jou JR, Chou P (2007) Optic neuritis among national health insurance enrollees in Taiwan, 2000–2004. Neuroepidemiology 29:250–254

    Article  PubMed  Google Scholar 

  12. Rudick RA (2001) Contemporary immunomodulatory therapy for multiple sclerosis. J Neuroophthalmol 21:284–291

    CAS  PubMed  Google Scholar 

  13. European Study Group on Interferon Beta-1b in Secondary Progressive MS (1998) Placebo-controlled multicenter randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491–1497

    Article  Google Scholar 

  14. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504

    Article  Google Scholar 

  15. Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP, Selhorst JB, Rose JW, Cooper JA, Rice G, Murray TJ, Sandrock AW (2002) Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 51:481–490

    Article  CAS  PubMed  Google Scholar 

  16. CHAMPS Study Group (2001) Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 132:463–471

    Article  Google Scholar 

  17. Wang AG, Lin YC, Wang SJ, Tsai CP, Yen MY (2006) Early relapse in multiple sclerosis-associated optic neuritis following the use of interferon b-1a in chinese patients. Jpn J Ophthalmol 50:537–542

    Article  CAS  PubMed  Google Scholar 

  18. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127

    Article  CAS  PubMed  Google Scholar 

  19. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489

    Article  CAS  PubMed  Google Scholar 

  20. Beck RW, Cleary PA (1993) Optic Neuritis Treatment Trial: one-year follow-up results. Arch Ophthalmol 111:773–775

    CAS  PubMed  Google Scholar 

  21. Perkin GD, Rose FC (1979) Optic neuritis and its differential diagnosis. Oxford Medical Publications, England

    Google Scholar 

  22. Optic Neuritis Study Group (2008) Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology 115:1079–1082

    Article  Google Scholar 

  23. Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR, Savino PJ, Guy JR, Trobe JD, McCrary JA III, Smith CH, Chrousos GA, Thompson HS, Katz BJ, Brodsky MC, Goodwin JA, Atwell CW (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326:581–588

    Article  CAS  PubMed  Google Scholar 

  24. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J (1999) A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 52(7):1479–1484

    CAS  PubMed  Google Scholar 

  25. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 329:1764–1769

    Article  CAS  PubMed  Google Scholar 

  26. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898–904

    Article  CAS  PubMed  Google Scholar 

  27. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sørensen PS, Rovaris M, Martinelli V, Hommes OR (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 357:1576–1582

    Article  CAS  PubMed  Google Scholar 

  28. Arnold AC (2005) Evolving Management of Optic Neuritis and Multiple Sclerosis. Am J Ophthalmol 139:1101–1108

    Article  PubMed  Google Scholar 

  29. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242–1249

    Article  CAS  PubMed  Google Scholar 

  30. Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z (2005) Interferon beta-1b Multiple Sclerosis Study Group of Japan. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 64:621–630

    CAS  PubMed  Google Scholar 

  31. Mikol DD (2001) Treat early, but treat hard: Interferon-beta dose makes a difference. J Neuroophthalmol 21:237–239

    CAS  PubMed  Google Scholar 

  32. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53:1107–1114

    CAS  PubMed  Google Scholar 

  33. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112

    Article  CAS  PubMed  Google Scholar 

  34. Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, Lebrun C, Moreau T, Vermersch P, Fontaine B, Lyon-Caen O, Gout O (2007) Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 13:256–259

    Article  CAS  PubMed  Google Scholar 

  35. Warabi Y, Matsumoto Y, Hayashi H (2007) Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 252:57–61

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, National Taiwan University Hospital, 7, Chung-Shan South Road, Taipei, Taiwan

    Yan-Ming Chen, Fung-Rong Hu & Jieh-Ren Jou

  2. Department of Ophthalmology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan

    Yan-Ming Chen

  3. Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan

    Chih-Chao Yang

  4. Department of Ophthalmology, Cathay General Hospital, Taipei, Taiwan

    I-Hua Wang

Authors
  1. Yan-Ming Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chih-Chao Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I-Hua Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fung-Rong Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jieh-Ren Jou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jieh-Ren Jou.

Additional information

The authors have no proprietary interest in the research presented here

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, YM., Yang, CC., Wang, IH. et al. The effect of interferon β-1a on optic neuritis relapse in patients with multiple sclerosis. Graefes Arch Clin Exp Ophthalmol 248, 231–235 (2010). https://doi.org/10.1007/s00417-009-1207-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-009-1207-2

Keywords

Search

Navigation